Introducing Agonist Redirected Checkpoint (ARC) Therapeutics for Cancer Immunotherapy and Inflammation.


Shattuck Labs is developing a breakthrough platform for immunotherapy, which harnesses the human immune system to improve survival for patients battling cancer and inflammatory disease. Shattuck's proprietary technology represents the next evolutionary step in cancer therapy by endowing one molecule with multiple functions, building directly on the clinical success of Opdivo, Keytruda and Tecentriq, with applicability across a broad range of tumor types. We expect to enter clinical trials by early 2019.


Shattuck Labs is headquartered in Austin, Texas, with R&D operations in Research Triangle Park, North Carolina. Shattuck was founded in 2016 and is privately-held. Our mission is to develop highly differentiated therapies that are designed to improve outcomes for patients. We foster a company culture that strives to be humble, thoughtful, ever curious, and fun (because life is too short). We let science and data lead us, in all of our endeavors, always. Most of all, we feel privileged and lucky to be part of Shattuck, and to have the opportunity to contribute to science and ultimately to improve human health.


Shattuck has attracted a world-class group of executives, directors and scientific advisors to lead development of the ARC platform and guide corporate strategy.


Josiah C. Hornblower
CEO, Chairman, and Co-founder

Taylor H. Schreiber, MD, PhD
Chief Scientific Officer, Co-founder

Neil Gibson, PhD
Chief Scientific Officer, Biologics, COI Pharma

David G. Lowe, PhD
Investor and Entrepreneur

G. Walter Loewenbaum
Chairman of the Board & Executive Committee, Luminex

Tyler Brous
Portfolio Manager, Lennox Capital Partners, LP

George Golumbeski, PhD
Venture Partner, Arch Venture Partners


Josiah C. Hornblower
CEO, Chairman, and Co-founder

Taylor H. Schreiber, MD, PhD
Chief Scientific Officer, Co-founder

Lini Pandite, MD
Chief Medical Officer

Andrew R. Neill, MBA
Vice President of Corporate Development & Strategy

George Fromm, PhD
Vice President of Research & Development

Erin Ator Thomson, JD
General Counsel

Tom Lampkin, PharmD
Vice President of Regulatory Affairs


Keith T. Flaherty, MD
Dana-Farber / Harvard Cancer Center

Charles G. Drake, MD, PhD
Columbia University Medical Center

Johann De Bono, MD, PhD
The Institute of Cancer Research

Dmitry Gabrilovich, MD, PhD
The Wistar Institute

Matthew Hellmann, MD
Memorial Sloan Kettering Cancer Center

Kurt Schalper MD, PhD
Yale School of Medicine


Shattuck has attracted an outstanding base of early investors and partners as a result of its immunology and development expertise and the transformative potential of the ARC platform.